对于进展性脑疾病的MIF贡献
Agata Matejuk1, Gil Benedek2, Richard Bucala3
1Department of Immunology, Collegium Medicum, University of Zielona Góra, Zielona Góra, Poland. a.matejuk@cm.uz.zgora.pl.
Journal of neuroinflammation
|January 4, 2024
概括
慢性炎症是进展性脑疾病的基础. 巨细胞迁移抑制因子 (MIF) 是一种关键的炎症调解剂,也是阿尔茨海默氏症和多发性硬化症等神经系统疾病的潜在治疗点.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 渐进性脑疾病带来了重大的社会和经济负担,需要新的治疗策略.
- 慢性,未解决的炎症是许多进展性脑功能障碍的常见病理基础.
- 巨细胞迁移抑制因子 (MIF) 是一种炎症调解剂,在中枢神经系统 (CNS) 中具有多种作用,包括发育和神经炎症.
研究的目的:
- 审查巨细胞迁移抑制因子 (MIF) 在主要神经疾病的发病过程中的关键作用.
- 突出MIF作为潜在的生物标志物和中枢神经系统疾病的治疗目标.
主要方法:
- 本综述综合了当前关于MIF参与神经疾病的研究.
- 专注于其在神经炎症和疾病进展中的功能.
主要成果:
- 在多发性硬化症 (MS),阿尔茨海默氏症 (AD) 和质母细胞瘤 (GBM) 的基础上,MIF在神经炎症过程中发挥着重要作用.
- 它在中枢神经系统中的多方面的作用使其成为治疗干预的有希望的候选人.
结论:
- MIF是各种神经疾病的发展和进展的关键因素.
- 针对MIF提供了一个有前途的途径,用于开发用于削弱大脑疾病的新疗法.
关键词:
AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD ADD was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was星系细胞瘤是一个星系细胞瘤.多元期权基金和多元期权基金.在MSMSMSMSMSMSMSMSMSMSMS中,我们可以看到神经退行发生神经退行.神经炎症是一种神经炎症.更多相关视频
09:49Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
Published on: January 20, 2023
3.2K
09:46Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
4.7K
相关概念视频
Alzheimer's Disease: Overview
491
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
491
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Parkinson's Disease: Overview
553
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
553
